Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade D 47.86 0.44% 0.21
RARE closed up 0.44 percent on Friday, February 23, 2018, on approximately normal volume.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical RARE trend table...

Date Alert Name Type % Chg
Feb 23 Inside Day Range Contraction 0.00%
Feb 23 Wide Bands Range Expansion 0.00%
Feb 22 50 DMA Resistance Bearish 0.44%
Feb 22 Multiple of Ten Bearish Other 0.44%
Feb 22 Wide Bands Range Expansion 0.44%
Feb 21 Expansion Pivot Sell Setup Bearish Swing Setup 3.35%
Feb 21 Doji - Bullish? Reversal 3.35%
Feb 21 Earnings Movers Other 3.35%
Feb 21 Wide Bands Range Expansion 3.35%
Feb 20 50 DMA Resistance Bearish -0.66%

Older signals for RARE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Is RARE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 91.35
52 Week Low 41.67
Average Volume 592,251
200-Day Moving Average 54.2972
50-Day Moving Average 48.806
20-Day Moving Average 48.842
10-Day Moving Average 46.624
Average True Range 2.9842
ADX 16.69
+DI 24.55
-DI 25.36
Chandelier Exit (Long, 3 ATRs ) 51.9424
Chandelier Exit (Short, 3 ATRs ) 50.6226
Upper Bollinger Band 56.4978
Lower Bollinger Band 41.1862
Percent B (%b) 0.44
BandWidth 31.349249
MACD Line -0.8511
MACD Signal Line -0.831
MACD Histogram -0.0201
Fundamentals Value
Market Cap 2.04 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -7.10
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.55
Resistance 3 (R3) 50.41 49.39 50.10
Resistance 2 (R2) 49.39 48.70 49.45 49.95
Resistance 1 (R1) 48.62 48.28 48.11 48.76 49.80
Pivot Point 47.60 47.60 47.34 47.66 47.60
Support 1 (S1) 46.83 46.91 46.32 46.97 45.92
Support 2 (S2) 45.81 46.49 45.87 45.77
Support 3 (S3) 45.04 45.81 45.62
Support 4 (S4) 45.18